Global Gene Therapy Market Size, Worth and Forecast with CAGR Through 2022

Gene Therapy Market: Gene therapies are generally meant for one time or short duration treatments, they are customized to individuals confined to small patient populations. Therefore, manufacturing firms are expected to seek premium prices for these therapies.

PUNE, INDIA - August 14, 2019 /MarketersMedia/ —

Growing at a CAGR of over x% the global gene therapy market is forecast to hit $363 million by 2022 from $x million in 2017. Strengthened by recent approvals of Kymriah, Yescarta and Luxturna in the US, and a committed European, Japanese and Chinese environment, gene therapy is set to become a significant player in the bio-pharmaceutical industry. The space covers many therapeutic areas specifically, oncology, rare diseases, Parkinson’s, HIV, severe combined immuno-deficiencies (SCID) and hemophilia. Gene Therapy Market is driven by over 2,200 clinical trials globally, with over 55% of this occurring in the US, followed by Europe, Canada and China. Recently, in November 2017, the FDA indicated that gene therapies will now qualify for a fast approval process, which will bring more therapies to market faster. However, the space also has significant challenges, such as manufacturing logistics, reimbursement and its high cost. This 310 page market analysis cutting-edge report tackles this growing but challenging industry, it highlights its strengths, weaknesses and opportunities and provides a comprehensive account of major companies, clinical trials and technological advancement.

Get Free Sample Copy of Gene Therapy Market Research Report at https://www.reportsnreports.com/contacts/requestsample.aspx?name=1370259

Since the FDA approved Kymriah (tisagenlecleucel), Yescarta (Axicabtagene ciloleucel) and Luxturna (voretigene neparvovec-rzyl) in 2017, the US gene therapy space has expanded significantly, underlined by the fact that over 55% of completed and ongoing trials are located in this geographic. Growth in the gene therapy industry has resulted in new commercial initiatives and the emergence of new startups and spin-off biotechs. Furthermore, gene therapy specifically has raised well over $600 million of venture capital in the last five years. Early stage companies have raised seed, Series A and Series B investment steadily since the market took off, including Spark Therapeutics, Avalanche Biotech, uniQure, Voyager Therapeutics, Editas Medicine and GenSight.

This report provides the reader with:

• Current Global Gene Therapy Market Worth and Forecast with CAGR Through 2022
• Sub-Market Worth by Therapeutic Area (Cancer, Rare Diseases, Cardiovascular, Neurological, Ocular) and Forecast with CAGR Through 2022
• Sub-Market Worth by Geography (Americas, Europe, RoW) and Forecast with CAGR Through 2022
• Sub-Market Worth by Technology (Gene Product, Service, Viral Vectors) and Forecast with CAGR Through 2022
• Insight into gene therapy technologies, challenges associated with developing therapeutic genes and disadvantages of gene therapy.
• Full outline of the gene therapy industry from the formative years through to products discovered during 1990 and 2017.
• Detailed descriptions of commercialized products approved between 2003 and 2017 that include: Gendicine, Rexin-G, Oncorine, Neovasculgen, Glybera, Imlygic, Strimvelis, Zalmoxis, Kymriah, Yescarta and Luxturna.
• Description of seven of the Phase III product candidates that include: Generx, Collategene, LentiGlobin, Lenti-D, VM-202, Invosa and GS-010.
• Description of 21 Phase II product candidates that are set to have significant market share.
• Commercialization status of gene therapies in by geographic region
• Evaluation of gene therapy pricing
• Description of the firstever warranty offer by GSK for Strimvelis.
• A detailed analysis of various types of viruses used as vectors.
• Description of clinical applications of gene therapy and the various genetic and infectious diseases addressed by gene therapy.
• Description of 77 companies that are directly and indirectly associated with gene therapy industry.

Get Discount on Global Gene Therapy Market Analysis & Forecast to 2022
https://www.reportsnreports.com/contacts/discount.aspx?name=1370259

Key Questions Answered in this Report:

• What is the size of gene therapy market?
• What is the CAGR and market size over the next five years?
• What are the different sub-markets and their worth/CAGR over the next five years?
• What is gene augmentation therapy?
• What is suicide gene therapy?
• How is ex vivo gene delivery different from in vivo gene delivery?
• What are the types of gene therapies classified on the basis of targeted cell types?
• What is the role of CRISPR technology in gene therapy?
• What are the approved gene therapy products?
• How many gene therapy product candidates have reached the Phase III stage?
• How many Phase II gene therapy product candidates are there?
• What is the commercialization status of gene therapies in E.U. member countries?
• What are the prices of gene therapy products?
• What are the reasons for this extortionate pricing of gene therapies?
• Which company is offering warranty for its gene- therapy product?
• What is the current strength of gene therapy industry?
• Is it true that the real strength of gene therapy industry is based on the number of clinical trials?
• What is the total number of ongoing clinical trials as of 2017?
• What is the distribution of clinical trials by geography?
• Which countries are associated with gene therapy clinical trials?
• What are the major indications addressed by the clinical trials?
• Which genes are transferred in these clinical trials?
• How many Big Pharma are associated with the gene therapy industry?
• What are non-viral and viral vectors?
• What are the various features of viral vectors?
• Which viral vectors are predominantly used in gene therapy clinical trials?
• What are the major diseases addressed by therapeutic genes?
• Where is the gene therapy market heading, and what opportunities and challenges will it face?

Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=1370259

Major Pointers From Table of Contents:
1.0 Introduction
2.0 Gene Therapy: The Basics
3.0 Historic Overview of Gene Therapy
4.0 Gene Therapy Phase III Product Candidates
5.0 Gene Therapy Phase II Product Candidates
6.0 Commercialization, Cost and Warranty of Gene Therapies
7.0 The Strength of Gene Therapy Industry
8.0 Vectors for Gene Delivery
9.0 Clinical Applications of Gene Therapy
10.0 Market Analysis
11.0 Manufacturing of Viral Vectors and Logistics
12.0 Company Profiles

Contact Info:
Name: Ganesh Pardeshi
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1370259-global-gene-therapy-market-analysis-forecast-to-2022.html

Source URL: https://marketersmedia.com/global-gene-therapy-market-size-worth-and-forecast-with-cagr-through-2022/88908116

Source: MarketersMedia

Release ID: 88908116

Latest News

Wisconsin Senate to vote on firing agriculture secretary

Dec 13, 2019

MADISON, Wis. — Wisconsin's Republican-controlled Senate prepared Tuesday to fire the state agriculture secretary appointed by Democratic Gov. Tony Evers, the latest in a series of skirmishes between the governor and the GOP that comes as Wisconsin is losing dairy farmers at a record pace. Republicans and Evers have been fighting since before Evers even took office. Republicans convened a lame-duck session to pass laws weakening Evers' power in December. This summer, Evers used his expansive veto to reshape the GOP-passed state budget, resulting in attempts in court and through a constitutional amendment to weaken his veto authority. And on...

Draghi stepped in during euro's darkest hour

Dec 13, 2019

FRANKFURT, Germany — Mario Draghi leaves as head of the European Central Bank credited with having rescued the eurozone from disaster with a well-timed phrase and bold action to back up his words. He expanded the bank's arsenal of crisis-fighting tools with new and unconventional policies, measures that he and others say helped end a financial crisis in 2010-2012 and create millions of jobs in the 19-country monetary union. Yet the closing days of his term have hardly been a victory lap. His departure is accompanied by an unusually public dispute among ECB board members over stimulus policies he pushed...

The Latest: Draghi says his legacy not dented by criticism

Dec 13, 2019

FRANKFURT, Germany — The Latest on the European Central Bank and Mario Draghi's last new conference as its president (all times local): 2:55 p.m. As he winds up his eight-year term, European Central Bank President Mario Draghi says his legacy isn't dented by the unusual public criticism by some ECB officials of a key part the bank's last stimulus package. Draghi said Thursday that criticism of the decision to purchase bonds with newly printed money was "part and parcel of the ongoing debate." He said "we have discussions, everybody has discussions." Draghi spoke at his last news conference before former...

Trump seeks to block California as global climate leader

Dec 13, 2019

WASHINGTON — The Trump administration on Wednesday moved to topple California as a leading voice against climate change, charging in a federal lawsuit that the state exceeded its constitutional authority by joining with a Canadian province in a program to cut climate-damaging fossil fuel emissions. In addition to adding to a long list of lawsuits pitting California and other Democratic-led states against the Trump administration over proposed federal environmental rollbacks, the new lawsuit raises constitutional questions about whether President Donald Trump's inaction on climate change amounts to an international and domestic policy that states must follow, constitutional experts say. Wednesday's...

Appeals court set to hear arguments over Trump's tax returns

Dec 13, 2019

NEW YORK — An appeal panel is poised to hear President Donald Trump's lawyers argue that New York state investigators should not be permitted to see his tax returns. The arguments before the 2nd U.S. Circuit Court of Appeals are set for Wednesday. They come after a lower-court judge tossed out Trump's challenge to a subpoena on his longtime accountant for records since 2011. Manhattan District Attorney Cyrus R. Vance Jr. wants the records for a criminal probe stemming in part from payments to two women who claim affairs with the president. Trump's lawyers say the Constitution prohibits states from...

Search
Financial Markets

About Us

Established in 2015, The Upstocker provides insights on financial reports, commentary, and investment data to traders so that you can make better investment decisions.

Contact us: sales[at]theupstocker.com

Subscribe Now!